Furthermore, heat shock protein inhibitors (i.e., HSP90), inhibitors of apoptosis (IAP), and proteosome inhibitors have been shown to enhance the expression of a variety of NKG2D ligands in different cancer types via the activation of DDR pathway mediators [203,204,205]. This evidence concerns the gene KLRK1 and cancer.